Resident
Asleson, Demi, BSc, PharmD
Residency Program
LMPS
Project Title
Intermittent vs continuous IV infusion tacrolimus in pediatric hematopoietic stem cell transplantation
Investigators
Jennifer Kendrick, BSc, BSc (Pharm), ACPR, PharmD, Roxane Carr, BSc, BSc (Pharm), ACPR, PharmD, FCSHP, BCPS; Jacob Rozmus, BSc, PhD, MD
Abstract
Graft versus host disease (GVHD) occurs in 30-70% of patients receiving allogenic hematopoietic stem cell transplants (HSCT). Tacrolimus is used to help prevent the development of GVHD, more specifically severe GVHD, and prolong patient survival. Tacrolimus is a calcineurin inhibitor and first choice agent in the pediatric population due to improved tolerability over cyclosporine. There is limited data comparing intravenous (IV) intermittent and continuous tacrolimus dosing in the pediatric population. The purpose of this study is to compare the proportion of therapeutic drug levels and to describe the prevalence of aGVHD and safety between the intermittent and continuous dosing methods.
